Pharma Outsourcing – Find the Right Partner (2026)

Obesity-drug pioneers win Lasker Award

This year’s Lasker Prize in Clinical Research has been awarded to three researchers for their discoveries in GLP-1-based drugs that, according to the jury, “hav...

Automate E2E Image Analysis Pipelines

ZEISS arivis Pro - Your End-to-End Scientific Image Analysis Software.

Level up your medical expertise

Learn from innovative industry speakers from leading MedTech companies at ZEISS Quality Innovation Days.

Nordic Regulatory experts: Improving biotech chances of Succ

Why is it that so many biotech companies fail? And what are the tools needed to change that fact?

Framgång för Hansa i amerikansk fas III-studie – ”Vi är begeistrade”

Lundbaserade Hansa Biopharmas transplantationsläkemedel imlifidase klarade det primära effektmåttet i en registreringsgrundande fas III-studie i USA.

Accurate removal of prostate tissue

Medical robots play an important role in diagnostics

Festo Expands its Portfolio with Multilayer Manifolds

Manufacturers of medical and laboratory equipment now receive solutions from a single source

Novo Nordisk skrotar distansarbete

Vid årsskiftet slopar Novo Nordisk möjligheten till distansarbete. Enligt bolagets nya vd ska det påskynda beslutsfattandet och förbättra den kommersiella genom...

Astra Zenecas nya viktminskningsbolag ska bevara muskelmassa

Astra Zeneca har fullföljt en option att köpa det schweiziska start up-bolaget Sixpeaks Bio, som utvecklar fetmabehandlingar.

Xspray fyller på inför USA-lansering – tar in 135 miljoner

Forskningsbolaget Xspray Pharma har beslutat att ta in 135 miljoner kronor via en nyemission med företrädesrätt för befintliga aktieägare.

Major advances in IVF labs in the last few decades

Since the introduction of in vitro fertilisation several decades ago, many developments have been made in the field, and the main part of that development has t...

Pfizer jagar fotfäste på obesitasmarknaden – förvärvar Metsera

Pfizer förvärvar amerikanska viktminskningsbolaget Metsera. Affären är initialt värd 4,9 miljarder dollar, motsvarande cirka 46 miljarder kronor, men kan stiga ...

On the hunt for high throughput diagnostics

Global diagnostics companies and laboratories are in a race against time to adapt testing capacity to current demand. Due to the global COVID 19 pandemic, the d...

No longer afraid of the dentist.

Teaching robot with piezo technology

BioArctic moves forward with its candidate for Parkinson’s

BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.

Mathias Uhlén’s protein atlas is recognised as a global resource

The Human Protein Atlas is the first database in Sweden to be designated a Global Core Biodata Resource. According to Mathias Uhlén, this is a quality hallmark ...

Genredigering ska ge sänkta blodfetter

Nya genmodifierande behandlingar är under utveckling för att varaktigt reglera halterna av blodfetter, och därmed minska risken för hjärt-kärlsjukdomar. Ett av ...

Immunterapibolag tar in 339 miljoner

Immunterapibolaget Asgard Therapeutics har tagit in 30 miljoner euro, motsvarande omkring 339 miljoner kronor, i en finanseringsrunda.

ZEISS Quality Innovation Days: April 15 – 19, 2024

Be there when industry experts give exciting insights into different applications and trends in 90 minutes on various theme days.

He saved lives with his theories – was ostracised and ended up in a mental hospital

Hungarian doctor Ignaz Semmelweis (1818-1865) undoubtedly possessed plenty of persistence, diligence and sound reasoning skills – but he was hardly blessed with...

Italian pharmaceutical company buys rights to immunotherapy from Sanofi

Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).

The Swedish innovation model: “There is a paradox”

It is often said that Sweden is strong when it comes to innovation, but how well are we turning that innovation into actual medicines?

Novartis stämmer Astra Zeneca-bolag för påstått falska budskap

Novartis stämmer Alexion, Astra Zenecas enhet för sällsynta sjukdomar, som man anklagar för att ha lanserat “en falsk och vilseledande marknadsföringskampanj”.